PRNAF ALTERITY THERAPEUTICS LTD
Price Chart
Executive Summary
Alterity Therapeutics received positive FDA feedback following a Type C meeting on its Phase 3 development program for ATH434 in Multiple System Atrophy (MSA), confirming alignment on clinical pharmacology and non-clinical elements. This regulatory progress supports the company's path toward initiating a pivotal Phase 3 trial, with further discussions planned for mid-2026.
Actionable Insight
Traders should monitor upcoming catalysts, particularly the mid-2026 End-of-Phase 2 meeting with the FDA, which could provide further clarity on trial design and timelines. Positive outcomes may lead to increased investor confidence and potential share price appreciation, especially given the lack of approved disease-modifying therapies for MSA.
Key Facts
- Alterity Therapeutics received positive written feedback from the FDA after a Type C meeting regarding its Phase 3 program for ATH434 in MSA.
- FDA alignment was achieved on clinical pharmacology and non-clinical development components of the program.
- The company plans to seek further agreement on Chemistry, Manufacturing, and Controls (CMC) and Phase 3 trial design.
- An End-of-Phase 2 meeting is on track for mid-2026, a key milestone before initiating the pivotal Phase 3 trial.
- ATH434 has previously shown clinically meaningful efficacy in Phase 2 trials in MSA patients.
Financial Impact
No direct financial impact disclosed; however, regulatory de-risking increases the probability of future funding and partnership opportunities.
Risk Factors
- Regulatory feedback was positive but limited to only two of four key disciplines (clinical pharmacology and non-clinical); CMC and trial design remain pending.
- As a development-stage biotech, Alterity remains dependent on successful trial execution, future regulatory approvals, and external financing.
- No efficacy or safety data from Phase 3 trials are available yet, and prior Phase 2 results, while positive, were in small studies.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001437749-26-010134 |
| Document: athe20260330_6k.htm | 0001437749-26-010134 |
| Document: 0001437749-26-010134-index-headers.html | 0001437749-26-010134 |
| Document: 0001437749-26-010134-index.html | 0001437749-26-010134 |
| Document: 0001437749-26-010134.txt | 0001437749-26-010134 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Apr 30, 2026
23d ago
|
6-K
| — | awaiting T+5 | — | — |
|
Apr 29, 2026
24d ago
|
6-K
| $0.001100 $0.001100 | · 0.00% | ▼ −3.11% | $0.001100 (−0.00%) |
|
Apr 27, 2026
26d ago
|
6-K
| $0.001100 $0.001100 | · 0.00% | ▼ −0.40% | $0.001100 (−0.00%) |
|
Apr 22, 2026
4w ago
|
6-K
| $0.001100 $0.001100 | · 0.00% | ▼ −0.05% | $0.001100 (−0.00%) |
|
Apr 21, 2026
4w ago
|
6-K
| $0.001100 $0.001100 | · 0.00% | ▼ −1.08% | $0.001100 (−0.00%) |
|
Apr 20, 2026
4w ago
|
6-K
| $0.001100 $0.001100 | · 0.00% | ▼ −0.91% | $0.001100 (−0.00%) |
|
Apr 17, 2026
5w ago
|
6-K
| $0.001100 $0.001100 | · 0.00% | ▼ −0.55% | $0.001100 (−0.00%) |
|
Apr 15, 2026
5w ago
|
6-K
| $0.001100 $0.001100 | · 0.00% | ▼ −1.64% | $0.001100 (−0.00%) |
|
Apr 1, 2026
7w ago
|
6-K
| $0.001100 $0.001100 | · 0.00% | ▼ −3.77% | $0.001100 (−0.00%) |
|
Mar 30, 2026
7w ago
|
6-K
| $0.000200 $0.001100 | ▲ +450.00% | ▲ +445.70% | $0.001100 (+450.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access